Compounded medications are not FDA approved. FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed.
23 dated briefs on regulatory and market events that change what compounded-GLP-1 buyers face: FDA enforcement and rulemaking, adverse-event reporting, manufacturer price moves, approvals, and coverage changes. Each brief separates event date from publication and update dates, cites primary sources, and carries a change log. Investigational agents receive research-only coverage per the methodology. Last updated: 2026-10-15.
October 15 price re-read: no-membership month-to-month rates now start near $126 for tirzepatide and $87 for semaglutide
We re-read the compounded GLP-1 programs we track on their own pages on October 15, 2026. Eden now prints compounded tirzepatide at $129 and semaglutide at $99 a month with "No membership fees", replacing the $99 membership it required in July (all-in $298 and $198 then). Mondae prints $126 and $87 for one month. NexLife's standard cards are unchanged at $169 / $139 month-to-month and $139 / $119 a month on 12-month plans. Mochi Health moved to per-dose "as low as" prices with a separate membership, and Henry Meds prints no drug-specific price, so neither is in the cost tables. The index now holds 31 compounded tirzepatide programs ($85.58–$449 a month all-in, median $149) and 24 semaglutide programs ($49–$193.92, median $99).
What it means for cash-pay patients: the lowest figures in the index are sale prices, prepaid terms or "from" figures; compare the month-to-month column before you commit. Full tables: tirzepatide · semaglutide · dataset.
Change log: 2026-10-15 — initial publication.
Walmart will cover Ozempic and Mounjaro for employees with type 2 diabetes in 2027, but still no weight-loss GLP-1s
Event date: 2026-10-13 · Published: 2026-10-15 · Confidence: reported (news report, not a plan document)
CNBC reported on October 13, 2026 that Walmart will cover more than 250 prescriptions at no cost to employees in 2027, including Ozempic and Mounjaro for type 2 diabetes after a new prior authorization. According to the same report, Walmart still does not cover GLP-1s prescribed for weight loss. The details come from news reporting, not from a Walmart plan document we have read.
What it means for cash-pay patients: employees who want a GLP-1 for weight loss stay in the self-pay market. Source: CNBC, October 13, 2026.
Change log: 2026-10-15 — initial publication.
Ozari Health adds a second compounded plan in a paid press release (not yet in our index)
A paid GlobeNewswire release dated October 12, 2026 says Ozari Health now sells "Ozari One" (compounded semaglutide with B12 at $86 a month, billed $258 every three months; tirzepatide with B12 at $125 a month, billed $375 every three months; not available in California) and "Ozari Select" (semaglutide $175 to $99 and tirzepatide $235 to $140 a month, depending on billing length). We have not read these prices on Ozari's own pages, so Ozari is not in the cost tables.
What it means for cash-pay patients: a quarterly bill of $258 or $375 is the real first charge, and both plans rely on additive formulations of the kind FDA questioned in its September Empower letter. Source: GlobeNewswire release, October 12, 2026.
Change log: 2026-10-15 — initial publication.
FDA posts warning letters to two websites selling unapproved "generic" injectable semaglutide
FDA's Internet pharmacy warning letters 737806 (onlinegenericmedicine.com, "Semanat") and 737810 (cheapmedicineshop.com, "Semanext") say both sites sell unapproved, misbranded injectable semaglutide. Neither site is a U.S. compounding pharmacy or a telehealth program in our index.
What it means for cash-pay patients: "generic semaglutide" sold by overseas websites is not compounded semaglutide and is not legal to import for personal use; verify the pharmacy before you pay. Sources: FDA letter 737806 · FDA letter 737810.
Change log: 2026-10-15 — initial publication.
FDA updates its page on unapproved GLP-1 drugs: 28-day vial discard rule and compounding limits
FDA's "Concerns with Unapproved GLP-1 Drugs Used for Weight Loss" page, current as of October 1, 2026, gives a 28-day discard rule for compounded multi-dose GLP-1 vials, warns against semaglutide salt forms, states that retatrutide and cagrilintide cannot be used in compounding under federal law, and lists adverse-event reports as of May 31, 2026: 990 for compounded semaglutide and more than 730 for compounded tirzepatide. Which sections changed on October 1 is not marked on the page.
What it means for cash-pay patients: a vial that holds more than 28 days of doses may have to be discarded before it is empty, which changes the real cost per dose. Source: FDA, current as of 2026-10-01.
Change log: 2026-10-15 — initial publication.
Rhode Island Medicaid stops covering GLP-1s prescribed only for weight loss
Under Rhode Island's enacted FY2027 budget, Medicaid stopped covering Foundayo, Saxenda, Wegovy and Zepbound when prescribed solely for weight loss, effective October 1, 2026, according to a Tufts Health RITogether provider notice. Coverage continues for type 2 diabetes and other FDA-approved indications.
What it means for cash-pay patients: affected members face self-pay prices or stopping treatment. Source: Point32Health provider notice.
Change log: 2026-10-15 — initial publication.
CMS page: the Medicare GLP-1 Bridge runs through December 31, 2027
CMS's BALANCE Model page (last modified September 29, 2026) states that "The Medicare GLP-1 Bridge has been extended through December 31, 2027" and carries an FAQ about "the BALANCE Model not launching in Medicare in 2027". Per Medicare.gov, the Bridge covers Foundayo, Wegovy and the Zepbound KwikPen for a $50 copay for eligible people with a BMI of 35 or more, or lower BMI thresholds with listed conditions. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible for the Bridge; their Part D plan might cover a GLP-1 instead. Medicare open enrollment runs October 15 to December 7.
What it means for cash-pay patients: if you are on Medicare, check Bridge eligibility before paying cash for any compounded program. Sources: CMS BALANCE page · CMS Medicare GLP-1 Bridge page.
Change log: 2026-10-15 — initial publication.
Federal charges in a counterfeit Ozempic distribution case
FDA announced that federal prosecutors charged two people with conspiracy and smuggling over counterfeit Ozempic that court documents say was sourced from China and distributed between July 2023 and April 2024. An indictment is an allegation, not a finding of guilt.
What it means for cash-pay patients: buy brand GLP-1s only through licensed pharmacies or the manufacturers' own programs. Source: FDA press announcement.
Change log: 2026-10-15 — initial publication.
Novo Nordisk: about 90% of Wegovy pill prescriptions are self-pay
Novo Nordisk's Capital Markets Day U.S. operations deck says the Wegovy pill has passed 7 million prescriptions this year, with about 90% self-pay and about 80% of patients new to GLP-1 obesity drugs. NovoCare lists the pill at $149 (1.5 mg), $199 (4 mg) and $299 (9 and 25 mg) a month.
What it means for cash-pay patients: an FDA-approved semaglutide now sits inside the compounded price range at its starting doses. Source: Novo Nordisk CMD 2026 deck.
Change log: 2026-10-15 — initial publication.
FDA warning letter 738238 to Empower Pharmacy over compounded tirzepatide and semaglutide
FDA's warning letter to Empower Clinic Services, LLC dba Empower Pharmacy (Houston) says its tirzepatide/niacinamide and semaglutide/cyanocobalamin products "appear to be essentially copies of FDA-approved semaglutide and tirzepatide products" and cites sterile products "prepared, packed, or held under insanitary conditions". The company had 15 working days to respond.
What it means for cash-pay patients: ask your program which pharmacy fills your order and whether your formulation includes an additive; our pharmacy check shows how to look the pharmacy up. Source: FDA warning letters database (MARCS-CMS 738238).
Change log: 2026-10-15 — initial publication.
Mochi Health moves compounded GLP-1s to per-dose pricing
Event date: Mochi blog post published 2026-08-14, updated 2026-09-18 · Published: 2026-10-15 · Confidence: confirmed (company blog)
Mochi Health's post "New Per-Dose Pricing: What Changed" says compounded semaglutide now runs $60 to $99 a month and tirzepatide $90 to $199 by dose, with membership billed separately. Mochi's pages read on October 15 show only per-dose medication prices ("As low as $60" semaglutide, "As low as $90" tirzepatide) with the membership billed separately, so Mochi is listed without an all-in figure in our tables.
What it means for cash-pay patients: the entry price rises as the dose rises; ask for the price at your maintenance dose plus the membership. Source: Mochi Health blog.
Change log: 2026-10-15 — initial publication.
Still pending on October 15, 2026
Status check · Published: 2026-10-15
No final FDA decision has been published on the proposal (announced April 30, 2026; 91 FR 23431; comments closed July 30, 2026 under 91 FR 38719) to leave tirzepatide, semaglutide and liraglutide off the 503B bulks list. Lilly says retatrutide's application is planned for the first quarter of 2027, and no FDA decision on CagriSema had been published. Lilly reports third-quarter results on October 29, 2026; Lilly's commercial savings cards, the reduced Foundayo 2.5 mg and 5.5 mg prices and NovoCare's $199 Wegovy starter offer run through December 31, 2026; Lilly states no fixed end date for the Zepbound self-pay offer. No FDA recall of a compounded GLP-1 appears in openFDA enforcement data from September 1 through October 7, 2026, the latest date in that dataset.
NexLife cuts its flat-rate cards for September 2026; microdose and sublingual protocols expanded
NexLife announced a lower September 2026 rate card — compounded tirzepatide $169 month-to-month / $139 on 12 months (from $215 / $186) and semaglutide $139 / $119 (from $165 / $145) — plus expanded microdose (tirzepatide announced at $159–$129) and sublingual/ODT protocols, a named medical director (Dr. Adam Kennah). (Update 2026-10-15: NexLife's plan pages now name three state-licensed 503A pharmacies; the October cards are unchanged.) We re-read the standard cards on the live program pages on 2026-09-04 (matched); the microdose tirzepatide page still showed the prior card, so that card is listed as announced. Full change note: NexLife September 2026 price update; current table: compounded tirzepatide prices.
Oral Wegovy tablet launches at a $149 introductory rate
Event date: 2026-01 (approval 2025-12) · Published: 2026-08-09 · Discovered: on/around event date · Last updated: 2026-08-09
Novo Nordisk's oral semaglutide tablet — approved in December 2025 — reached the market in early 2026 with a $149/month introductory self-pay rate, putting an FDA-approved GLP-1 inside the compounded semaglutide price band for the first time. The tablet carries strict empty-stomach dosing rules; its price and the later Foundayo launch together form the brand context the August price check now benchmarks against.
Primary sources: FDA approval records (December 2025); Novo Nordisk launch and program materials · Change log: 2026-08-09 — initial publication.
TrumpRx lists Zepbound and Wegovy around $350
Event date: 2026-02 · Published: 2026-08-09 · Discovered: on/around event date · Last updated: 2026-08-09
The federal direct-purchase channel began listing both flagship obesity injectables at roughly $350/month, adding a third self-pay brand route beside LillyDirect ($299–$449 by dose) and NovoCare ($349 flat). For compounded-market shoppers the relevance is the benchmark: the approved-product comparison price most cash buyers face is now $299–$449 — the frame our compounded-vs-brand analysis uses without ever ranking the categories together.
Primary sources: program listings; manufacturer cash-pay program pages · Change log: 2026-08-09 — initial publication.
FDA issues a coordinated wave of warning letters over compounded GLP-1 marketing
Event date: 2026-02-19 · Published: 2026-08-09 · Discovered: on/around event date · Last updated: 2026-08-09
FDA sent roughly thirty warning letters to telehealth companies and sellers concerning the marketing of compounded GLP-1 drugs — approval-implying language, equivalence claims, and safety-and-efficacy assertions borrowed from approved products. The action addressed claims, not a product-quality finding against any single program; our enforcement explainer and 483-vs-warning-letter guide cover how to read letters like these.
Hims & Hers closes compounded GLP-1s to new patients
Event date: 2026-03-09 · Published: 2026-08-09 · Discovered: on/around event date · Last updated: 2026-08-09
The largest telehealth brand in weight care stopped new-patient enrollment in compounded GLP-1s and moved new starts to brand-name fulfillment — the clearest market signal of the post-shortage contraction this site's shortage-resolution explainer describes. Existing tracked programs continue under the patient-specific 503A pathway.
Zepbound KwikPens reach retail pharmacies at LillyDirect self-pay tiers
Event date: 2026-03-16 · Published: 2026-08-09 · Discovered: on/around event date · Last updated: 2026-08-09
Eli Lilly extended its $299–$449 self-pay tiers to Zepbound KwikPens at retail counters, including Walmart. For compounded-market shoppers this matters as context: the FDA-approved comparison price became a same-day retail option — the benchmark our compounded-vs-brand analysis prices against, without ever ranking the two categories together.
Event date: 2026-03-19 · Published: 2026-08-09 · Discovered: on/around event date · Last updated: 2026-08-09
FDA approved a 7.2 mg once-weekly semaglutide formulation (Wegovy HD), lifting the labeled ceiling from 2.4 mg based on the STEP-UP trial — with no direct top-dose trial against tirzepatide. NovoCare self-pay listed the tier at $399. Label reports at the top dose include altered skin sensation. Context: tirzepatide vs semaglutide in 2026.
Primary sources: FDA approval records (March 19, 2026); Novo Nordisk announcements; STEP-UP topline. · Change log: 2026-08-09 — initial publication.
FDA approves orforglipron (Foundayo) — first small-molecule GLP-1 pill
Event date: 2026-04-01 · Published: 2026-08-09 · Discovered: on/around event date · Last updated: 2026-08-09
FDA approved orforglipron, branded Foundayo: a once-daily oral GLP-1 with no food, water, or timing restrictions, launched from $149/month self-pay at the lowest dose ($25 with commercial savings cards; ~$50 Medicare Part D copays from July 1). An FDA-approved product at a price inside the compounded semaglutide band changes the outside option for every cash buyer — see the August price check for the current field.
FDA proposes removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list
Event date: 2026-04-30 · Published: 2026-08-09 · Discovered: on/around event date · Last updated: 2026-08-09
A proposed rule would formally exclude the three GLP-1s from the list of bulk substances outsourcing facilities may compound without patient-specific prescriptions — converting post-shortage enforcement posture into regulation for the 503B lane. The patient-specific 503A pathway, under which tracked programs operate, is not the subject of the proposal. Comment-period and finalization status will be tracked here.
Primary sources: Federal Register (proposed rule, April 30, 2026); FDA compounding pages · Change log: 2026-08-09 — initial publication.
Retatrutide phase 3 results published (research-only)
Event date: 2026-05-21 · Published: 2026-08-09 · Discovered: on/around event date · Last updated: 2026-08-09
Lilly has reported topline TRIUMPH results for retatrutide (figures not re-read this session; see Lilly's releases). Lilly plans to submit its application in the first quarter of 2027. Research-only coverage: retatrutide is not FDA approved, is not lawfully available as a compounded treatment, and no provider, pricing, or availability content applies; anything sold today under that name is unregulated gray-market material.
Primary sources: Eli Lilly topline releases; peer-reviewed publications as available · Change log: 2026-08-09 — initial publication.
FDA adverse-event tally for compounded tirzepatide passes 730 reports
Event date: 2026-05-31 · Published: 2026-08-09 · Discovered: on/around event date · Last updated: 2026-08-09
FDA's running count of adverse-event reports associated with compounded tirzepatide exceeded 730 as of May 31, 2026. Reports are raw, unadjudicated signals without denominators — not a risk rate — but recurring themes (dosing errors with multi-dose vials, product-quality questions) map directly onto the failure modes our vial-math and dosing-error guides exist to prevent. Report problems to FDA MedWatch.
Medicare obesity-medication coverage phase-in reaches the ~$50 copay tier
Event date: 2026-07-01 · Published: 2026-08-09 · Discovered: on/around event date · Last updated: 2026-08-09
Qualifying Medicare patients began accessing covered obesity medications at roughly a $50 monthly copay under the 2026 phase-in — a coverage door that, where it applies, undercuts every cash figure this site tracks, compounded or brand. Coverage is criteria-bound; the practical takeaway for eligible readers is to exhaust coverage checks before shopping the cash market this site documents.
Primary sources: CMS/HHS program materials; plan documentation · Change log: 2026-08-09 — initial publication.
Frequently asked questions
What changed for compounded GLP-1 buyers in October 2026?
In the month to October 15, 2026, FDA told Empower Pharmacy that its additive tirzepatide and semaglutide products appear to be essentially copies of approved drugs, FDA's GLP-1 page, updated October 1, includes a 28-day discard rule for multi-dose vials, and CMS's BALANCE page (modified September 29) confirms the Medicare GLP-1 Bridge runs through December 31, 2027. Prices moved too: Eden dropped its membership and now prints $129 tirzepatide and $99 semaglutide a month, while Mochi Health moved to per-dose "as low as" prices with a separate membership and Henry Meds prints no drug-specific price, so neither is in our cost tables. The 503B bulks-list proposal was still undecided.